95 results
424B3
CYDY
CytoDyn Inc.
16 Apr 24
Prospectus supplement
5:16pm
of oversight and controls. The consolidated complaint also asserts claims against one or more individual defendants for waste of corporate assets, unjust … and misleading statements and by failing to maintain an adequate system of oversight and controls. The
complaint also asserts claims against certain
424B3
CYDY
CytoDyn Inc.
16 Apr 24
Prospectus supplement
5:15pm
of oversight and controls. The consolidated complaint also asserts claims against one or more individual defendants for waste of corporate assets, unjust … and misleading statements and by failing to maintain an adequate system of oversight and controls. The
complaint also asserts claims against certain
424B3
CYDY
CytoDyn Inc.
19 Jan 24
Prospectus supplement
5:15pm
for COVID-19, the Company’s CD10 and CD12 clinical trials and its HIV BLA, and by failing to maintain an adequate system of oversight and controls … the monitoring and oversight of the clinical data. For additional information see Part I, Item 1, Note 8, Commitments and Contingencies – Legal
424B3
25qfbk4ph5cs0uii1
24 Oct 23
Prospectus supplement
6:01am
424B3
4btoq5vn4937ny4
10 Oct 23
Prospectus supplement
6:02pm
POS AM
94e 2s1h310
2 Oct 23
Prospectus update (post-effective amendment)
5:15pm
NT 10-K
fimkar 3gwawidr0ha4
30 Aug 23
Notice of late annual filing
5:15pm
424B3
s8doiu6ck360
11 Jul 23
Prospectus supplement
5:28pm
8-K
EX-99.1
zv5t1mc
28 Oct 22
CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data Management Issues
5:15pm